Number of other deaths (unrelated to SUDEP) · cases of SUDEP and matched controls (number of deaths due to SUDEP) and consecutive people with epilepsy from a tertiary care teaching…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Behaviour: occurrence of violent incidents (to self, others, or property) · people with primary delusional infestation
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Relapse · patients with schizophrenia
CBT showed no clear difference in global state: relapse compared with ALL OTHER PSYCHOLOGICAL THERAPIES (low certainty).
1 finding from 1 review
Patient readmissions · patients with schizophrenia
CBT showed no clear difference in global state: rehospitalisation* compared with ALL OTHER PSYCHOLOGICAL THERAPIES (low certainty).
1 finding from 1 review
Mental state: General ‐ clinically important change (no improvement) · patients with schizophrenia
CBT showed no clear difference in mental state: General ‐ clinically important change (no improvement) compared with ALL OTHER PSYCHOLOGICAL THERAPIES (low certainty).
1 finding from 1 review
Adverse effect/event: death ‐ any cause · patients with schizophrenia
CBT showed no clear difference in adverse effect/event: death ‐ any cause compared with ALL OTHER PSYCHOLOGICAL THERAPIES (low certainty).
1 finding from 1 review
Social functioning · patients with schizophrenia
1 finding from 1 review
QoL · patients with schizophrenia
1 finding from 1 review
Satisfaction with treatment: leaving the study early Endpoint data (events) · patients with schizophrenia
CBT may leads to lower satisfaction with treatment ‐ leaving the study early for any reason compared with ALL OTHER PSYCHOLOGICAL THERAPIES (low certainty).
1 finding from 1 review
Perceived need for surgery in adulthood · Children and adolescents (aged 16 years or younger) with prominent lower front teeth (Class III malocclusion)
The review found no eligible studies for this question.
1 finding from 1 review
ANB · Children and adolescents (aged 16 years or younger) with prominent lower front teeth (Class III malocclusion)
It is very uncertain whether facemask (RME) or modified facemask changes ANB compared with other non-surgical orthodontic treatments (mini maxillary… (very low certainty).
1 finding from 1 review
Overjet · Children and adolescents (aged 16 years or younger) with prominent lower front teeth (Class III malocclusion)
It is very uncertain whether facemask (RME) or modified facemask changes overjet compared with other non-surgical orthodontic treatments (mini maxillary… (very low certainty).
1 finding from 1 review
Scar severity ‐ 585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC) ‐ Vancouver Burn Scar (VBS) (Higher score = worse scar appearance) ‐ hypertrophic scars ‐ · participants with hypertrophic and keloid scars
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Scar severity ‐ 585‐nm PDL versus TAC ‐ patient self‐assessment of scar improvement of 50% or higher, or patients considering the scar better or much better ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes scar severity ‐ 585‐nm PDL versus TAC ‐ patient self‐assessment of… compared with other treatments (very low certainty).
1 finding from 1 review
OR 0.81
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus TAC: sequelae ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐ 585‐nm… compared with other treatments (very low certainty).
1 finding from 1 review
RR 0.09 [0.01, 1.45]
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus TAC ‐ mild to moderate pain related to treatment ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐ 585‐nm… compared with other treatments (very low certainty).
1 finding from 1 review
RR 0.9
Studies not reported
Very low
Scar severity ‐ 585‐nm PDL versus 5‐FU ‐ patient self‐assessment of scar improvement of 50% or higher ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes scar severity ‐ 585‐nm PDL versus 5‐FU ‐ patient self‐assessment of… compared with other treatments (very low certainty).
1 finding from 1 review
OR 0.81
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus 5‐FU ‐ mild to moderate pain related to treatment ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐ 585‐nm… compared with other treatments (very low certainty).
1 finding from 1 review
RR 0.9
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus 5‐FU ‐ purpura ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐ 585‐nm… compared with other treatments (very low certainty).
1 finding from 1 review
RR 4.2
Studies not reported
Very low
Scar severity ‐ 585‐nm PDL versus TAC plus 5‐FU ‐ patient self‐assessment of scar improvement of 50% or higher ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes scar severity ‐ 585‐nm PDL versus TAC plus 5‐FU ‐ patient… compared with other treatments (very low certainty).
1 finding from 1 review
RR 0.89 [0.61, 1.29]
Studies not reported
Very low